Molecular mechanisms in heart failure - Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis

被引:114
作者
Hilfiker-Klemer, Denise
Landmesser, Ulf
Drexler, Helmut
机构
[1] Hannover Med Sch, Dept Cardiol, D-3000 Hannover, Germany
[2] Hannover Med Sch, Dept Angiol, D-3000 Hannover, Germany
关键词
D O I
10.1016/j.jacc.2006.07.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure is a final common pathway in cardiovascular disease, as a result of sustained pressure overload (i.e., hypertension), myocardial ischemia or infarction, volume overload (i.e., mitral regurgitation), or inherited and acquired cardiomyopathies. Heart failure is a major health care burden, and despite significant therapeutic advances, morbidity and mortality in heart failure remain unacceptably high. Therefore, novel insights into pathophysiology and molecular mechanisms of heart failure are required to develop novel therapeutic approaches. In this review we highlight several advances in the understanding of molecular pathways involved in cardiac hypertrophy, inflammatory signaling (i.e., tumor necrosis factor-alpha, interleukin-6), and oxidant stress that may play a key role in altering transcriptional regulatory networks regulating adaptation or maladaptation, and consequently, the transition to overt heart failure. In this respect we focus on paracrine mechanisms (vascular endothelial growth factor, CCN1) and intracellular signaling (interleukin-6-glycoprotein 130-signal transducer and activator of transcription-3). In addition, we highlight the impact of current treatment options on these molecular pathways and their potential impact on progression of heart failure.
引用
收藏
页码:A56 / A66
页数:11
相关论文
共 114 条
[1]   Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging [J].
Anker, SD ;
Doehner, W ;
Rauchhaus, M ;
Sharma, R ;
Francis, D ;
Knosalla, C ;
Davos, CH ;
Cicoira, M ;
Shamim, W ;
Kemp, M ;
Segal, R ;
Osterziel, KJ ;
Leyva, F ;
Hetzer, R ;
Ponikowski, P ;
Coats, AJS .
CIRCULATION, 2003, 107 (15) :1991-1997
[2]   Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo [J].
Antos, CL ;
McKinsey, TA ;
Frey, N ;
Kutschke, W ;
McAnally, J ;
Shelton, JM ;
Richardson, JA ;
Hill, JA ;
Olson, EN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :907-912
[3]   Life and death of cardiac stem cells - A paradigm shift in cardiac biology [J].
Anversa, P ;
Kajstura, J ;
Leri, A ;
Bolli, R .
CIRCULATION, 2006, 113 (11) :1451-1463
[4]   Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload [J].
Badorff, C ;
Ruetten, H ;
Mueller, S ;
Stahmer, M ;
Gehring, D ;
Jung, F ;
Ihling, C ;
Zeiher, AM ;
Dimmeler, S .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :373-381
[5]   Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression -: Role of enhanced vascular superoxide production [J].
Bauersachs, J ;
Bouloumié, A ;
Fraccarollo, D ;
Hu, K ;
Busse, R ;
Ertl, G .
CIRCULATION, 1999, 100 (03) :292-298
[6]   Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice [J].
Bendall, JK ;
Cave, AC ;
Heymes, C ;
Gall, N ;
Shah, AM .
CIRCULATION, 2002, 105 (03) :293-296
[7]   Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload [J].
Brancaccio, M ;
Fratta, L ;
Notte, A ;
Hirsch, E ;
Poulet, R ;
Guazzone, S ;
De Acetis, M ;
Vecchione, C ;
Marino, G ;
Altruda, F ;
Silengo, L ;
Tarone, G ;
Lembo, G .
NATURE MEDICINE, 2003, 9 (01) :68-75
[8]   Integrin signalling: The tug-of-war in heart hypertrophy [J].
Brancaccio, Mara ;
Hirsch, Emilio ;
Notte, Antonella ;
Selvetella, Giulio ;
Lembo, Giuseppe ;
Tarone, Guido .
CARDIOVASCULAR RESEARCH, 2006, 70 (03) :422-433
[9]   The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice [J].
Bueno, OF ;
De Windt, LJ ;
Tymitz, KM ;
Witt, SA ;
Kimball, TR ;
Klevitsky, R ;
Hewett, TE ;
Jones, SP ;
Lefer, DJ ;
Peng, CF ;
Kitsis, RN ;
Molkentin, JD .
EMBO JOURNAL, 2000, 19 (23) :6341-6350
[10]   Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy [J].
Cappola, TP ;
Kass, DA ;
Nelson, GS ;
Berger, RD ;
Rosas, GO ;
Kobeissi, ZA ;
Marbán, E ;
Hare, JM .
CIRCULATION, 2001, 104 (20) :2407-2411